Clinicopathological findings for adenocarcinoma of the esophagogastric junction

The prognose for adenocarcinoma of the esophagogastric junction (AEG) is worse than that for other gastric carcinoma. Siewert et al. recommended the extended total gastrectomy for type II and type III tumors, and transhiatal esophagectomy for type I. We have experience with 40 AEG cases, in which no recurrence occurred at the stump of the esophagus. The 3-year surcical rates were 50%, 56.3%, 56.3%, and 32.1% for Stages I, IIA+IIB, III, and IV, respectively. These data indicate that, more intensive adjuvant chemotherapy might be beneficial for patients with relatively early stage disease, namely, Stages I, IIA and IIB.